NCT03755804 2026-02-23
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
Clinical Trials
44 trialsNCT04685616 2026-02-18
RADAR
University College, London
Phase 3 Recruiting
NCT02227199 2025-11-18
BV-ICE
University of Washington
Phase 1/2 Completed
NCT07002216 2025-11-03
BrECADD
University of Miami
Phase 2 Recruiting
NCT01508312 2025-10-21
Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT05922904 2025-10-10
PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01868451 2025-07-09
Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase NA Active not recruiting
NCT01703949 2025-06-11
Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma
University of Washington
Phase 2 Active not recruiting
NCT03057795 2025-05-07
Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma
City of Hope Medical Center
Phase 2 Active not recruiting
NCT06377566 2025-04-20
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05595447 2025-03-12
Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma
Hospital Regional de Alta Especialidad del Bajio
Phase 2/3 Recruiting
NCT06761911 2025-01-07
BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma
Dalian Medical University
Phase 4 Not yet recruiting
NCT03712202 2024-11-06
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
City of Hope Medical Center
Phase 2 Active not recruiting
NCT02191930 2024-08-23
BVB
University of Cologne
Phase 2 Completed
NCT04378647 2024-02-26
BRESELIBET
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Recruiting
NCT03013933 2024-02-22
Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
City of Hope Medical Center
Phase 1 Completed
NCT06201507 2024-01-12
BV-AVD-R Treatment Children Hodgkin's Lymphoma
Beijing Children's Hospital
Phase 2 Unknown
NCT02398240 2023-10-26
Brentuximab for Newly Diagnosed Hodgkin Disease
New York Medical College
Phase 2 Completed
NCT02098512 2022-10-27
Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients
New York Medical College
Phase 1/2 Unknown
NCT02292979 2022-08-19
BREACH
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT03302728 2022-05-19
EpiBrentlen
Peter MacCallum Cancer Centre, Australia
Phase 1 Completed
NCT02429375 2022-05-12
Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT01578967 2021-12-07
Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase NA Completed
NCT02686346 2021-12-07
BV-ICE
The Lymphoma Academic Research Organisation
Phase 1/2 Completed
NCT02298283 2021-07-26
BRAPP2
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT02227433 2020-12-22
FIL_BVHD01
Fondazione Italiana Linfomi - ETS
Phase 2 Completed
NCT02505269 2020-08-24
Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
Massachusetts General Hospital
Phase 2 Completed
NCT03474133 2020-07-21
BASALT
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 2 Unknown
NCT01657331 2020-07-17
SGN+Benda
Columbia University
Phase 1/2 Completed
NCT01476410 2020-02-17
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma
Northwestern University
Phase 2 Unknown
NCT02254239 2019-12-12
Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Mayo Clinic
Phase 1 Terminated
NCT02169505 2019-11-27
Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03527628 2019-11-18
(Optimist)
King Abdullah International Medical Research Center
Phase 2 Unknown
NCT03440788 2019-10-28
Patient-reported and Clinical Outcomes in Adults With Relapsed or Refractory Hodgkin's Lymphoma Receiving Brentuximab Vedotin
Multinational Center for Quality of Life Research, Russia
Unknown
NCT02243436 2019-04-24
Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 1/2 Completed
NCT01569204 2018-10-29
Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma
University of Cologne
Phase 2 Completed
NCT03540849 2018-05-30
BV-ALLO
University Hospital, Caen
Phase 2 Unknown
NCT02567851 2018-05-11
BREVITY
University of Birmingham
Phase 2 Completed
NCT01393717 2018-04-26
Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma
City of Hope Medical Center
Phase 2 Completed
NCT02280993 2018-03-13
Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 1 Unknown
NCT01534078 2018-02-20
Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma
Massachusetts General Hospital
Phase 2 Completed
NCT02244021 2018-02-09
BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEV
Fondazione Italiana Linfomi - ETS
Phase 2 Completed
NCT02408042 2017-06-27
Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)
Western Regional Medical Center
Phase 1/2 Withdrawn
NCT02275598 2014-10-27
Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma
University of Modena and Reggio Emilia
Phase 2 Unknown